| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T126945-5mg |
5mg |
期货  |
| |
| T126945-10mg |
10mg |
期货 |
|
| 英文别名 | QLYKJCMUNUWAGO-GAJHUEQPSA-N | MS-29577 | GDOIKKMNCIMDAO-UHFFFAOYSA-N | SR-01000945071 | Taranabant | N-((2S,3S)-4-(4-Chlorophenyl)-3-(3-cyanophenyl)butan-2-yl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide | N-[(1S,2S)-3-(4-Chloro-phenyl)-2 |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Taranabant |
| 生化机理 | Taranabant 是一种用于治疗肥胖症的新型无环大麻素-1 受体反向激动剂（CB1 拮抗剂）。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 激动剂 |
| 作用机制 | 大麻素 CB1 受体反向激动剂 |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide |
| INCHI | 1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1 |
| InChi Key | QLYKJCMUNUWAGO-GAJHUEQPSA-N |
| Smiles | CC(C(CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F |
| Isomeric SMILES | C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F |
| PubChem CID | 11226090 |
| 分子量 | 515.97 |
| 溶解性 | Soluble in DMSO to 52 mM |
|---|---|
| 分子量 | 516.000 g/mol |
| XLogP3 | 6.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 8 |
| 精确质量Exact Mass | 515.159 Da |
| 单同位素质量Monoisotopic Mass | 515.159 Da |
| 拓扑极表面积Topological Polar Surface Area | 75.000 Ų |
| 重原子数Heavy Atom Count | 36 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 776.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Foloppe N, Benwell K, Brooks TD, Kennett G, Knight AR, Misra A, Monck NJ. (2009) Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.. Bioorg Med Chem Lett, 19 (15): (4183-90). [PMID:19520572] |
| 2. Lin LS, Ha S, Ball RG, Tsou NN, Castonguay LA, Doss GA, Fong TM, Shen CP, Xiao JC, Goulet MT et al.. (2008) Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.. J Med Chem, 51 (7): (2108-14). [PMID:18333607] |
| 3. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A et al.. (2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.. Cell Metab, 7 (1): (68-78). [PMID:18177726] |
首页
400-620-6333
